FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3083096714> ?p ?o ?g. }

• W3083096714 endingPage "251" @default.
• W3083096714 startingPage "249" @default.
• W3083096714 abstract "Pneumonitis is an uncommon but potentially fatal adverse event of both radiotherapy (RT) [ [1] Whitfield A.G. Lannigan R. Bond W.H. Fatal post-radiation pneumonitis. Lancet. 1954; 267: 117-119 Abstract PubMed Scopus (3) Google Scholar ] and anti-PD-1/PD-L1 immune checkpoint inhibitors (ICIs) for non-small cell lung cancer (NSCLC [ [2] Suresh K. Voong K.R. Shankar B. Forde P.M. Ettinger D.S. Marrone K.A. Kelly R.J. Hann C.L. Levy B. Feliciano J.L. Brahmer J.R. Feller-Kopman D. Lerner A.D. Lee H. Yarmus L. D’Alessio F. Hales R.K. Lin C.T. Psoter K.J. Danoff S.K. Naidoo J. Pneumonitis in non-small cell lung Cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors. J. Thorac. Oncol. 2018; 13: 1930-1939 Abstract Full Text Full Text PDF PubMed Scopus (170) Google Scholar ]. Symptomatic radiation (RT-) pneumonitis following chemoradiation can occur in up to 30% of patients, with 1%–16% of them requiring supplemental oxygen and 2% resulting in death [ 3 O’Rourke N. Roqué I Figuls M. Farré Bernadó N. Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst. Rev. 2010; 6: CD002140 PubMed Google Scholar , 4 Chun S.G. Hu C. Choy H. Komaki R.U. Timmerman R.D. Schild S.E. Bogart J.A. Dobelbower M.C. Bosch W. Galvin J.M. Kavadi V.S. Narayan S. Iyengar P. Robinson C.G. Wynn R.B. Raben A. Augspurger M.E. MacRae R.M. Paulus R. Bradley J.D. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-Cell lung Cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. J. Clin. Oncol. 2017; 35: 56-62 Crossref PubMed Scopus (412) Google Scholar , 5 Palma D.A. Senan S. Tsujino K. Barriger R.B. Rengan R. Moreno M. Bradley J.D. Kim T.H. Ramella S. Marks L.B. De Petris L. Stitt L. Rodrigues G. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int. J. Radiat. Oncol. Biol. Phys. 2013; 85: 444-450 Abstract Full Text Full Text PDF PubMed Scopus (410) Google Scholar ]. The incidence of ICI-related (ICI-) pneumonitis following anti-PD-1/PD-L1 monotherapy or combinations, ranges from 1%–10% [ [6] Topalian S.L. Hodi F.S. Brahmer J.R. Gettinger S.N. Smith D.C. McDermott D.F. Powderly J.D. Carvajal R.D. Sosman J.A. Atkins M.B. Leming P.D. Spigel D.R. Antonia S.J. Horn L. Drake C.G. Pardoll D.M. Chen L. Sharfman W.H. Anders R.A. Taube J.M. McMiller T.L. Xu H. Korman A.J. Jure-Kunkel M. Agrawal S. McDonald D. Kollia G.D. Gupta A. Wigginton J.M. Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012; 366: 2443-2454 Crossref PubMed Scopus (8830) Google Scholar , [7] Nishino M. Ramaiya N.H. Awad M.M. Sholl L.M. Maattala J.A. Taibi M. Hatabu H. Ott P.A. Armand P.F. Hodi F.S. PD-1 inhibitor-related pneumonitis in advanced Cancer patients: radiographic patterns and clinical course. Clin. Cancer Res. 2016; 22: 6051-6060 Crossref PubMed Scopus (289) Google Scholar ]. Recently, the addition of 1 year of maintenance anti-PD-L1 therapy after definitive chemoradiation has become a new standard-of-care for patients with medically inoperable stage III NSCLC. This is based on the findings of a phase III trial called PACIFIC, in which maintenance durvalumab significantly reduced cancer progression, and improved overall survival (HR 0.68) [ [8] Antonia S.J. Villegas A. Daniel D. Vicente D. Murakami S. Hui R. Kurata T. Chiappori A. Lee K.H. de Wit M. Cho B.C. Bourhaba M. Quantin X. Tokito T. Mekhail T. Planchard D. Kim Y.C. Karapetis C.S. Hiret S. Ostoros G. Kubota K. Gray J.E. Paz-Ares L. de Castro Carpeño J. Faivre-Finn C. Reck M. Vansteenkiste J. Spigel D.R. Wadsworth C. Melillo G. Taboada M. Dennis P.A. Özgüroğlu M. Investigators P. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N. Engl. J. Med. 2018; 379: 2342-2350 Crossref PubMed Scopus (1432) Google Scholar , [9] Antonia S.J. Villegas A. Daniel D. Vicente D. Murakami S. Hui R. Yokoi T. Chiappori A. Lee K.H. de Wit M. Cho B.C. Bourhaba M. Quantin X. Tokito T. Mekhail T. Planchard D. Kim Y.C. Karapetis C.S. Hiret S. Ostoros G. Kubota K. Gray J.E. Paz-Ares L. de Castro Carpeño J. Wadsworth C. Melillo G. Jiang H. Huang Y. Dennis P.A. Özgüroğlu M. Investigators P. Durvalumab after Chemoradiotherapy in stage III non-small-Cell lung Cancer. N. Engl. J. Med. 2017; 377: 1919-1929 Crossref PubMed Scopus (2218) Google Scholar ]. However, the benefits of this additive therapy is not without risk. While preclinical studies and clinical observations support potential immunologic synergy between RT and ICIs, there is also potential for increased toxicity [ [10] Deng L. Liang H. Burnette B. Beckett M. Darga T. Weichselbaum R.R. Fu Y.X. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 2014; 124: 687-695 Crossref PubMed Scopus (1225) Google Scholar , [11] Golden E.B. Demaria S. Schiff P.B. Chachoua A. Formenti S.C. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol. Res. 2013; 1: 365-372 Crossref PubMed Scopus (497) Google Scholar ]. For example, in the PACIFIC study, an absolute increase in rates of RT-pneumonitis as well as ICI-pneumonitis was seen in patients treated with durvalumab when compared to chemoradiation alone (RT-pneumonitis - any grade: 20% vs. 16%, grade 3+: 1.5% vs. 0.4%; ICI-Pneumonitis - any grade: 13% vs. 8%, respectively) [ [8] Antonia S.J. Villegas A. Daniel D. Vicente D. Murakami S. Hui R. Kurata T. Chiappori A. Lee K.H. de Wit M. Cho B.C. Bourhaba M. Quantin X. Tokito T. Mekhail T. Planchard D. Kim Y.C. Karapetis C.S. Hiret S. Ostoros G. Kubota K. Gray J.E. Paz-Ares L. de Castro Carpeño J. Faivre-Finn C. Reck M. Vansteenkiste J. Spigel D.R. Wadsworth C. Melillo G. Taboada M. Dennis P.A. Özgüroğlu M. Investigators P. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N. Engl. J. Med. 2018; 379: 2342-2350 Crossref PubMed Scopus (1432) Google Scholar ]. Similarly, a large single institution retrospective series of stage IV NSCLC patients who received ICI and subsequently developed ICI-pneumonitis similarly found numerically increased rates of ICI- pneumonitis in the subset of patients who had previously received definitive-intent thoracic RT [ [12] Voong K.R. Hazell S.Z. Fu W. Hu C. Lin C.T. Ding K. Suresh K. Hayman J. Hales R.K. Alfaifi S. Marrone K.A. Levy B. Hann C.L. Ettinger D.S. Feliciano J.L. Peterson V. Kelly R.J. Brahmer J.R. Forde P.M. Naidoo J. Relationship between prior radiotherapy and checkpoint-inhibitor pneumonitis in patients with advanced non-small-Cell lung Cancer. Clin. Lung Cancer. 2019; 20: e470-e479 Abstract Full Text Full Text PDF PubMed Scopus (42) Google Scholar ]. Given the morbidity associated with pneumonitis and its increasing relevance in stage III NSCLC, our ability to understand the real-world incidence and to optimally identify those at risk for both RT-pneumonitis and ICI-pneumonitis is crucial. Herein, we will review the findings of a retrospective study focusing on the real-world experience of durvalumab after chemoradiation in an Asian population of patients with stage III NSCLC, compare and contrast these findings with those of the flagship PACIFIC study and other published data, and examine how these data inform future questions on RT-pneumonitis in stage III NSCLC. Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancerLung CancerVol. 146PreviewStage III non-small-cell lung cancer (NSCLC) is a heterogeneous set of conditions including potentially resectable disease and unresectable NSCLC. Long-term outcomes are poor with a 5-year overall survival (OS) rate of 15–35 % for stage IIIA and 3–10 % for stage IIIB according to the AJCC 7th edition. Unresectable locally advanced (LA)-NSCLC accounts for about 30–50 % of stage III NSCLC [1]. Randomized phase III trials have shown the superiority of concurrent chemo-radiotherapy (CCRT) compared with sequential chemoradiotherapy in patients with unresectable LA-NSCLC [2,3]. Full-Text PDF" @default.
• W3083096714 created "2020-09-11" @default.
• W3083096714 creator A5044692746 @default.
• W3083096714 creator A5082410046 @default.
• W3083096714 date "2020-12-01" @default.
• W3083096714 modified "2023-10-14" @default.
• W3083096714 title "Radiation pneumonitis after definitive chemoradiation and durvalumab for non-small cell lung cancer" @default.
• W3083096714 cites W2037171241 @default.
• W3083096714 cites W2046701188 @default.
• W3083096714 cites W2052727153 @default.
• W3083096714 cites W2061126241 @default.
• W3083096714 cites W2101760296 @default.
• W3083096714 cites W2160834915 @default.
• W3083096714 cites W2161523978 @default.
• W3083096714 cites W2508623887 @default.
• W3083096714 cites W2528393079 @default.
• W3083096714 cites W2753065806 @default.
• W3083096714 cites W2893321040 @default.
• W3083096714 cites W2893824814 @default.
• W3083096714 cites W2927363814 @default.
• W3083096714 cites W2958220850 @default.
• W3083096714 cites W3028746215 @default.
• W3083096714 doi "https://doi.org/10.1016/j.lungcan.2020.08.022" @default.
• W3083096714 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32958455" @default.
• W3083096714 hasPublicationYear "2020" @default.
• W3083096714 type Work @default.
• W3083096714 sameAs 3083096714 @default.
• W3083096714 citedByCount "6" @default.
• W3083096714 countsByYear W30830967142021 @default.
• W3083096714 countsByYear W30830967142022 @default.
• W3083096714 countsByYear W30830967142023 @default.
• W3083096714 crossrefType "journal-article" @default.
• W3083096714 hasAuthorship W3083096714A5044692746 @default.
• W3083096714 hasAuthorship W3083096714A5082410046 @default.
• W3083096714 hasConcept C121608353 @default.
• W3083096714 hasConcept C126322002 @default.
• W3083096714 hasConcept C126838900 @default.
• W3083096714 hasConcept C143998085 @default.
• W3083096714 hasConcept C2776256026 @default.
• W3083096714 hasConcept C2777701055 @default.
• W3083096714 hasConcept C2777714996 @default.
• W3083096714 hasConcept C2777742743 @default.
• W3083096714 hasConcept C2779524853 @default.
• W3083096714 hasConcept C2780030458 @default.
• W3083096714 hasConcept C2908954928 @default.
• W3083096714 hasConcept C509974204 @default.
• W3083096714 hasConcept C71924100 @default.
• W3083096714 hasConceptScore W3083096714C121608353 @default.
• W3083096714 hasConceptScore W3083096714C126322002 @default.
• W3083096714 hasConceptScore W3083096714C126838900 @default.
• W3083096714 hasConceptScore W3083096714C143998085 @default.
• W3083096714 hasConceptScore W3083096714C2776256026 @default.
• W3083096714 hasConceptScore W3083096714C2777701055 @default.
• W3083096714 hasConceptScore W3083096714C2777714996 @default.
• W3083096714 hasConceptScore W3083096714C2777742743 @default.
• W3083096714 hasConceptScore W3083096714C2779524853 @default.
• W3083096714 hasConceptScore W3083096714C2780030458 @default.
• W3083096714 hasConceptScore W3083096714C2908954928 @default.
• W3083096714 hasConceptScore W3083096714C509974204 @default.
• W3083096714 hasConceptScore W3083096714C71924100 @default.
• W3083096714 hasLocation W30830967141 @default.
• W3083096714 hasOpenAccess W3083096714 @default.
• W3083096714 hasPrimaryLocation W30830967141 @default.
• W3083096714 hasRelatedWork W1879151775 @default.
• W3083096714 hasRelatedWork W2064979843 @default.
• W3083096714 hasRelatedWork W2133367262 @default.
• W3083096714 hasRelatedWork W2384648089 @default.
• W3083096714 hasRelatedWork W2392185351 @default.
• W3083096714 hasRelatedWork W2417657575 @default.
• W3083096714 hasRelatedWork W3009822716 @default.
• W3083096714 hasRelatedWork W3021216473 @default.
• W3083096714 hasRelatedWork W3032810950 @default.
• W3083096714 hasRelatedWork W3083096714 @default.
• W3083096714 hasVolume "150" @default.
• W3083096714 isParatext "false" @default.
• W3083096714 isRetracted "false" @default.
• W3083096714 magId "3083096714" @default.
• W3083096714 workType "article" @default.